Phosphodiesterase type 5 (PDE5) inhibitor.[2]

Udenafil is a PDE5 inhibitor taken by mouth. In contrast to plasma, udenafil is more widely distributed in the prostate and dramatically raises levels of cAMP and cGMP [1].

In patients with benign prostatic hyperplasia (BPH) who received a single 200 mg dose of udenafil 1 hour before transurethral resection of the prostate (TURP), the concentration of udenafil in prostate tissue was 2028.6 ± 360.8 ng/g and in plasma was 463.7 ± 39.1 ng/mL, resulting in a tissue-to-plasma (T/P) ratio of 4.4.[2]
Udenafil significantly increased cAMP and cGMP levels in both prostate tissue and plasma compared to the control group (no PDE5 inhibitor).[2]

Metabolism/Metabolites
Hepatic metabolism. Metabolized by CYP3A4 and CYP3A5.

---

One hour before transurethral resection of the prostate (TURP) following a single oral dose of 200 mg udenafil, the drug concentration in prostate tissue was 2028.6 ± 360.8 ng/g, and the drug concentration in plasma was 463.7 ± 39.1 ng/mL. [2]
The tissue/plasma (T/P) ratio of udenafil was 4.4, significantly higher than that of tadalafil (T/P ratio of 1.3). [2]
The intermediate half-life of udenafil has been reported to be 7.3–12.1 hours. [2]

In a 12-week clinical trial, treatment-related adverse events with udenafil were generally mild to moderate. No serious adverse events were reported. [1] The most common treatment-related adverse events were facial flushing (reported by 10.5% of patients in the 100 mg group and 23.2% of patients in the 200 mg group), headache (1.8% in the 100 mg group and 8.9% in the 200 mg group), nasal congestion (3.5% in the 100 mg group and 7.1% in the 200 mg group), and conjunctival injection (3.5% in the 100 mg group and 7.1% in the 200 mg group). [1] Chest discomfort was reported by 5.4% of patients in the 200 mg group. [1] Myalgia and color vision disturbances were not reported. [1] Only two patients (in the 200 mg group) discontinued treatment due to adverse events (flushing/headache and chest pain). [1]
No clinically significant changes were observed in laboratory tests, electrocardiograms, or blood pressure. [1]

[1]. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53.

[2]. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107(12): p. 1943-7.

Udenafil is a sulfonamide drug. Udenafil is a novel phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not currently approved in the United States, the European Union, or Canada. Udenafil is a benzylsulfonamide derivative with vasodilatory activity. Udenafil selectively inhibits phosphodiesterase type 5 (PDE5), thereby inhibiting the degradation of cyclic guanosine monophosphate (cGMP) in the smooth muscle of the corpora cavernosa and corpus spongiosum of the penis; inhibition of cGMP degradation leads to prolonged muscle relaxation, vasodilation, and engorgement of the corpora cavernosa, thus prolonging the duration of penile erection. The drug has no significant inhibitory effect on the PDE11 isoenzyme. PDE11 inhibitors may be associated with significant myalgia.
Drug Indications
It has been studied for the treatment of erectile dysfunction and hypertension. Mechanism of Action Udenafil inhibits cGMP-specific phosphodiesterase type 5 (PDE5), an enzyme responsible for degrading cGMP in the corpora cavernosa of the penis. Penile erection during sexual stimulation is due to increased blood flow to the penis caused by relaxation of the penile arteries and smooth muscle of the corpora cavernosa. This response is mediated by the release of nitric oxide (NO) from nerve endings and endothelial cells, which stimulates smooth muscle cells to synthesize cGMP. Cyclic guanosine monophosphate (cGMP) causes smooth muscle relaxation, increasing blood flow into the corpora cavernosa. Udenafil enhances erectile function by inhibiting phosphodiesterase type 5 (PDE5), through a mechanism that increases cGMP levels. Pharmacodynamics Udenafil is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. Udenafil is a PDE5 inhibitor with a half-life of 7.3–12.1 hours. [2]
PDE5 inhibitors are known to improve erectile dysfunction and lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH), and their mechanism of action may be through increasing the levels of cyclic nucleotides (cAMP and cGMP) in the prostate and plasma. [2]
The high T/P ratio of udenafil suggests that it is more widely distributed in prostate tissue than in plasma and may have a longer duration of action. [2]
This study supports the feasibility of using PDE5 inhibitors such as udenafil to treat lower urinary tract symptoms and erectile dysfunction caused by benign prostatic hyperplasia. [2]

C25H36N6O4S

516.66

516.251

268203-93-6

Udenafil-d7;1175992-76-3

135413547

White to off-white solid powder

1.35g/cm3

697ºC at 760 mmHg(计算值)

157-159°C

375.3ºC(计算值)

2.83E-19mmHg at 25°C(计算值)

1.648

5.606

2

8

11

36

894

0

IYFNEFQTYQPVOC-UHFFFAOYSA-N

InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)

3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide

DA-8159, DA 8159, DA8159, Udenafil, trade name: Zydena

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ≥ 33 mg/mL (~63.87 mM)

Solubility in Formulation 1: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)